<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: This study was an attempt to evaluate and correlate serum interleukin-12 (IL-12) with different circulating markers in newly diagnosed type-2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) for possible progression of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: For this study, we recruited 1968 family members of diabetics and 349 had abnormal <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Out of 349 subjects, 197 were T2DM as per American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association guidelines and further investigated for <z:hpo ids='HP_0001626'>cardiovascular abnormalities</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>63 T2DM have high sensitive C-reactive protein (hsCRP)&gt;3.0mg/l and cardiovascular complications </plain></SENT>
<SENT sid="4" pm="."><plain>Overall, 150 subjects, 50 healthy, 50 T2DM (D1) and 50 T2DM with cardiovascular complications (D2) were enrolled and investigated for soluble markers </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The levels of serum <z:chebi fb="105" ids="17234">glucose</z:chebi>, proinflammatory cytokines (IL-6, IL-12, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor), <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> markers [vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (VCAM-1), inter-cellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1), nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi>] and <z:chebi fb="23" ids="18059">lipid</z:chebi> abnormality were highest in D2 group </plain></SENT>
<SENT sid="6" pm="."><plain>Correlation and regression study showed that IL-12 was dependent on hsCRP, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, VCAM-1, ICAM-1 and <z:chebi fb="23" ids="18059">lipids</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The multivariate stepwise regression analysis demonstrates that hsCRP contributes significantly for variance of IL-12 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: This study reveals that, even first-time diagnosis of T2DM, subjects with higher <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and abnormal <z:chebi fb="23" ids="18059">lipids</z:chebi> have elevated IL-12, <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and proinflammatory markers </plain></SENT>
<SENT sid="9" pm="."><plain>Further increased hsCRP enhance IL-12 which up-regulate <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> progression </plain></SENT>
</text></document>